title: Hyperferritinemia as indicator for intravenous immunoglobulin treatment in reactive macrophage activation syndromes.
abstract: The underlying mechanisms of reactive macrophage activation syndromes (rMAS) are not understood in detail, and there is no specific treatment. This observational study was prompted by intravenous immunoglobulin (IVIG), dramatically halting two distinct rMAS episodes in the same patient. We evaluated the potential benefits of IVIG administration in treating fulminant rMAS and the usefulness of monitoring serum ferritin levels as an indication for emergency treatment with IVIG. Ten females and 10 males experiencing 22 episodes of rMAS were recruited on the basis of serum ferritin levels >or=10,000 microg/l and/or direct evidence of haemophagocytosis in 11 intensive care units in secondary and tertiary care hospitals in Switzerland between October 1993 and May 2000. In individual patients, serially measured ferritin was closely related to disease activity. Abrupt increases of up to >100,000 microg/l could be observed within hours. Rapid and profound beneficial effects of emergency IVIG treatment were seen in 12 episodes of rMAS accompanied by a prompt decrease of serum ferritin. IVIG produced partial or delayed improvements in 5 patients. No apparent effects were seen in 5 patients. IVIG was only successful if started early during the ferritin run-up to peak values. In conclusion, IVIG is effective in at least a subgroup of adult rMAS when started at the beginning of the macrophage activation process. The monitoring of serum ferritin levels might be helpful in detecting macrophage activation in order to commence IVIG treatment early enough.
authors.affiliation: Department of Internal Medicine, Zieglerspital, Bern, Switzerland. urban.emmenegger@hcuge.ch
authors.forename: U
authors.initials: U
authors.lastname: Emmenegger
authors.forename: U
authors.initials: U
authors.lastname: Frey
authors.forename: A
authors.initials: A
authors.lastname: Reimers
authors.forename: C
authors.initials: C
authors.lastname: Fux
authors.forename: D
authors.initials: D
authors.lastname: Semela
authors.forename: P
authors.initials: P
authors.lastname: Cottagnoud
authors.forename: P J
authors.initials: PJ
authors.lastname: Spaeth
authors.forename: K A
authors.initials: KA
authors.lastname: Neftel
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D001773:Blood Cells; D005260:Female; D005293:Ferritins / Q000097:blood*; D006402:Hematologic Diseases / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D016756:Immunoglobulins, Intravenous; D008262:Macrophage Activation / Q000187:drug effects* / Q000502:physiology*; D008297:Male; D008875:Middle Aged; D010587:Phagocytosis; D016706:Still's Disease, Adult-Onset / Q000150:complications; D013577:Syndrome; D016896:Treatment Outcome
chemical_list: D016756:Immunoglobulins, Intravenous; D005293:Ferritins